Answers are grounded in this paper and cite their sources.
Case report demonstrates discordant FDG and DOTATATE PET uptake in progressive small cell lung cancer, highlighting dual-tracer imaging for tailoring radionuclide therapy.
A 54-year-old man with progressive small cell lung cancer underwent ¹⁸F-FDG and ⁶⁸Ga-DOTATATE PET/CT before radionuclide therapy. ¹⁸F-FDG PET/CT evaluated disease extent and identified metabolically active lesions. ⁶⁸Ga-DOTATATE PET/CT showed high SSTR expression in bone lesions and the pancreatic tail. Discordant hepatic uptake suggested tumor heterogeneity. The two scans provided complementary information on disease activity and therapeutic target expression, supporting patient selection and individualized planning for an SSTR-targeted radionuclide therapy–based comprehensive treatment strategy.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: